PHILADELPHIA – Big scientific goals, grand partnering ambitions, and a strong tolerance for risk are common hallmarks among the CEOs and founders of emerging platform companies. But what sets platform players apart from other biopharma ventures hasn't always been clear. Setting out to shed some light on the subject during the BIO convention, BioWorld asked the leaders of six dynamic companies about how they think about their businesses and what sets them apart.